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Abstract 
Background. Triple negative breast cancer (TNBC) is defined by the 
lack of estrogen receptors (ER), progesterone receptors (PR) and human 
epidermal growth factor receptor 2 (HER-2) expression. In this study we 
investigated response to neoadjuvant chemotherapy in TNBC patients and its 
impact on disease free (DFS) and overall survival (OS). 
Patients and methods. We identified 134 patients with stage I-III TNBC 
treated at Riga East University Hospital between 2009-2012. 48 patients with 
TNBC received neoadjuvant chemotherapy. Correlation of clinical and 
pathological parameters with pathologic complete response (pCR) rate, 
disease-free and overall survival measurements and organ specific relapse 
rates were analysed. 
Results. 48 patients with stage IIB-IIIC TNBC were included, 17 patients 
received anthracycline based, 31 patients anthracycline and taxane based 
neoadjuvant chemotherapy.  8 patients (16%) had pCR, 38 patients had 
incomplete response, 2 patients had disease progression during neoadjuvant 
chemotherapy.  pCR correlates with primary tumor size, but not with other 
clinical and pathological factors. At a median follow-up of  30 months, 100% 
patients who reached pCR were disease-free versus 55% in those without 
pCR (p=0.017). Overall survival was 100% in patients who had pCR versus 
50% in those without pCR (p=0.020). 2 patients are alive after disease 
recurrence, 20 patients died. The most common sites of disease recurrence 
were brain, lung and liver. 
Conclusions. Patients with TNBC who have a pCR in the breast and axillary 
nodes have a significantly improved disease-free and overall survival rate 
compared with patients with residual disease after neoadjuvant 
chemotherapy. 
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Introduction 
Triple-negative breast cancer (TNBC) is characterized by the lack of 
estrogen receptor (ER), progesterone receptor (PR) expression and human 
epidermal growth factor receptor 2 (HER-2) expression. These cancers occur 
in approximately 11-20% of all patients with breast cancer (Bauer, 2007; 
Perou, 2000), and are associated with unfavourable prognosis (Carey, 2006; 
Carey, 2007). Patients with TNBC do not benefit from molecular targeted 
treatments like endocrine therapy or trastuzumab, because they lack specific 
targets for these drugs.  
Neoadjuvant chemotherapy that was initially used for locally 
advanced breast cancer has become more common for patients with operable 
breast cancer. As a result more patients can undergo breast conserving 
surgery. In addition, neoadjuvant chemotherapy allows observing individual 
response to chemotherapy. It has been proved that long term outcome 
correlates with pathologic tumor response rates (von Minckwitz, 2012).  
In this study we have analyzed 48 TNBC patients who receive 
neoadjuvant anthracycline or anthracycline and taxane based chemotherapy 
to determine the incidence of pathologic complete response (pCR), the 
clinical and pathologic factors associated with it, and the clinical course of 
patients according to the pathologic tumor response. 
 
Patients and methods: 
We identified 134 patients with stage I-III TNBC treated at Riga East 
University Hospital Latvian Oncology Centre (Riga, Latvia) between 2009-
2012. 48 patients with TNBC who received neoadjuvant chemotherapy were 
included in the study. Inclusion of the patients was based on the following 
criteria:  1) receipt of at least 4 cycles of neoadjuvant chemotherapy; 2) 
availability of complete information on clinical TNM (cTNM) and 
pathologic stage (pTNM) in case of surgery; 3) response to treatment; and 4) 
no expression of ER, PR and HER-2. Patients with primary inflammatory 
carcinoma were not included in the analysis. Staging was performed 
according to American Joint Committee on Cancer guidelines (AJCC, 2010).  
 
Pathology Assessment 
 Pathologic diagnosis, ER, PR and HER-2 status were determined by 
core biopsy prior to systemic therapy. Core biopsy samples were analyzed at 
the Riga East University Hospital Pathology Center. Hematoxylin and eosin 
stained slides were assesed for histologic type of the tumor and histologic 
grade. Histologic grade was assessed using the Elston-Ellis modification of 
the Scarff-Bloom-Richardson grading system (Elston&Ellis, 1991). ER and 
PR status were determined by immunohistochemistry (IHC, DAKO LSAB+ 
methodology, monoclonal antibodies anti-ER (clone ER-1D5) and anti-PR 
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(clone PR-636)), tumours with less than 1% of stained cells were considered 
receptor negative (Hammond, 2010). HER-2 status was assessed by IHC 
(HercepTest, DakoCytomation, Glostrup, Denmark) according to the 
manufacturer‘s protocol. A negative HER2 test is defined as an IHC result of 
0 or 1+ (Wolff , 2007).   
 Pathologic response was determined by microscopic examination of 
the excised tumour and lymph nodes after neoadjuvant chemotherapy. 
Pathologic complete response (pCR) was defined as no residual invasive and 
in situ cancer in breast and lymph nodes (von Minckwitz, 2012). 
 
Statistical analyses 
χ² test was used to determine factors predictive of pCR. Parameters 
analyzed were age at the time of diagnosis, tumour histology, menopausal 
status, histologic grade, stage, clinical tumour (T) and nodal (N) score, type 
of neoadjuvant chemotherapy regimen, number of chemotherapy cycles, and 
type of surgery.  
Overall survival (OS) was calculated from the date of diagnosis to the 
date of last follow-up or death, disease-free survival (DFS) was calculated 
from the date of definitive surgery to the date of last follow-up or disease 
relapse using the method of Kaplan and Meier. The log-rank statistic was 
used for univariate comparisons of survival end points. 
 Statistical analyses were performed using IBM SPSS Statistics for 
Windows 22.0.  
 
Results: 
48 patients with TNBC, who received neoadjuvant chemotherapy at 
our institution were included in the analysis. Patient and tumor 
characteristics are shown in Table 1. The mean age of patients was 49 years 
(range 29-67years). All tumors were ductal carcinomas. 
17 patients (35%) received anthracycline based chemotherapy (FAC- 
doxorubicin 50mg/m², cyclophosphamide 500mg/m²,  fluorouracil 500mg/m² 
every 3 weeks), 31 patients (65%) received anthracycline and taxane based 
chemotherapy (AP- doxorubicin 60mg/m², paclitaxel 175mg/m² every 3 
weeks). Median number of neoadjuvant chemotherapy cycles was 5 (range 
4-7), patients received adjuvant chemotherapy if all planned therapy was not 
completed before surgery. Disease progression was observed in 2 patients; 
46 patients underwent surgery, 6 of them had breast conserving surgery, 40 
had mastectomy.  
8 patients (17%) experienced pCR compared with 38 patients (83%) 
with residual disease (RD). Correlation between clinical and pathological 
factors and pCR is shown in Table 2. Correlation was observed between 
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clinical primary tumor (cT) size and pCR; there was no correlation with age, 
stage, clinical nodal status and grade. 
Table 1. Patient Characteristics 
Characteristic No. of patients % 
Age range, years 
20-29 
30-39 
40-49 
50-59 
60-69 
Mean 
 
1 
8 
18 
10 
11 
49.4 
 
2 
17 
37 
21 
23 
Prechemotherapy T stage: 
T1 
T2 
T3 
T4 
 
4 
20 
13 
11 
 
8 
42 
27 
23 
Prechemotherapy N stage: 
N0 
N1 
N2 
N3 
 
3 
16 
10 
19 
 
6 
33 
21 
40 
Nuclear grade 
2 
3 
Unknown 
 
12 
34 
2 
 
25 
71 
4 
Neoadjuvant chemotherapy regimen 
Anthracycline based 
Anthracycline taxane based 
 
17 
31 
 
35 
65 
Surgical therapy 
Breast-conserving therapy 
Mastectomy 
 
6 
40 
 
13 
87 
Adjuvant radiation 
No 
Yes 
 
13 
33 
 
28 
72 
 
Of 45 patients with node-positive disease before starting treatment, 
23 (51%) were node negative at surgery. There was a trend for higher pCR 
rate for anthracycline and taxane based chemotherapy (19 versus 12% 
respectively) that did not reach statistical significance, probably because of 
the small sample size. 
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Table 2. Correlation between clinical and pathologic factors and pCR 
Characteristic pCR Non-pCR P value 
Prechemotherapy T stage 
T1 
T2 
T3 
T4 
 
1 
5 
2 
0 
 
3 
15 
11 
11 
0.042 
Prechemotherapy N stage 
N0 
N1 
N2 
N3 
 
0 
4 
2 
2 
 
3 
12 
8 
17 
0.459 
Nuclear grade 
2 
3 
Unknown 
 
2 
5 
1 
 
10 
29 
1 
0.874 
Neoadjuvant chemotherapy regimen 
Anthracycline based 
Anthracycline taxane based 
 
 
2 
6 
 
 
15 
25 
0.584 
Number of neoadjuvant 
chemotherapy cycles 
4-5 
6-7 
 
 
7 
1 
 
 
19 
19 
0.76 
 
At a median follow-up of  30 months (range 5.4 to 60.1 months), 
DFS was 100% in patients who reached pCR versus 55% in those without 
pCR (p=0.017) (Figure 1A).  
3 patients had pCR in breast, but residual disease in lymph nodes, 1of 
them had disease relapse. 2 patients had disease progression during 
neoadjuvant chemotherapy. 3 patients had local recurrence, 17 at distant sites 
(brain, n=6; liver, n=4; lung, n=5; bone, n=2). At a median follow-up of 30 
months, 6 patients (35%) in the FAC group  and 12 patients (38%) in the AP 
group had experienced disease relapse. Mean time to relapse was 32.1 
months (95%CI 26.2 to 44.6 months) in the FAC group versus 36.4 months 
(95%CI 33.3 to 49.6months) in the AP group, difference is not significant 
(p=0.686). 
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Figure 1. Relationship of pathologic brimary breast tumor and axillary lymph 
node response to disease-free survival (A) and overall survival (B) after 
neoadjuvant chemotherapy 
 
 
 
Overall survival was 100% in patients who had pCR versus 50% in 
those without pCR (p=0.020) (Figure 1B). 2 patients are alive after disease 
recurrence, 20 patients died, 7 patients (41%) in the FAC group and 13 
patients (42%) in the AP group, 2 patients died without documented 
progression. Mean survival time was 35.4 months (95%CI 26.2 to 44.6 
months) versus 41.4 months (95%CI 33.3 to 49.6 months) for FAC and AP 
groups respectively (p=0.551). 
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Discussion 
TNBC is an agressive subtype of breast cancer that lacks a 
therapeutic target, making chemotherapy the only systemic modality used in 
the treatment of this disease. The use of neoadjuvant chemotherapy has 
increased in recent years. This strategy offers a number of advantages, one of 
the most important is in vivo assessment of tumor response. 
Response of the tumor to neoadjuvant chemotherapy provides 
important prognostic information, prognosis of patients with a pCR in both 
the breast and axillary lymph nodes is much better than of those with 
residual disease (Liedtke, 2008; von Minckwitz, 2012). As shown in 
previous studies, patients with TNBC has higher rates of pCR following 
neoadjuvant chemotherapy than non-TNBC (Carey, 2007; Rastogi, 2008). 
Carey et al. found that TNBC and HER-2 positive breast cancers yield much 
higher pCR rates (27% and 36%, respectively) compared with the luminal 
subtypes, which had a pCR rate of 7% (p=0.01). A pCR rate of 17% was 
observed in our study, where majority of patients were diagnosed with 
locally advanced TNBC. 
 As pCR correlates with prognosis several strategies were evaluated 
to increase pCR rate. An important advance was the addition of taxanes to 
anthracycline-based chemotherapy. An increase in clinical responses and 
pCR rates has been reported in several trials with the addition of taxanes  
(Martin, 2011; Dieras, 2004;  Bear, 2003; Vinholes, 2001). A higher pCR 
rate was observed with anthracycline and taxane  versus anthracycline-based 
regimen (19% versus 12% respectively) in our study. Chemotherapy regimen 
without taxanes is not a current standard for neoadjuvant therapy for TNBC 
patients. FAC regimen was given because taxanes was not reimbursed for 
neoadjuvant treatment of breast cancer patients in 2009 and early 2010 in 
Latvia. 
Interim response guided neoadjuvant strategy was tested in Gepar 
Trio trial (von Minckwitz, 2008). Changing neoadjuvant chemotherapy on 
the basis of individual patient responses to the first two cycles improved DFS 
and OS for patients with luminal-type, but not for triple negative or HER-2 
positive breast cancer patients.  
Some novel neoadjuvant treatment regimens in TNBC incorporate 
platinum agents, based on the hypothesis of greater susceptibility of triple 
negative and BRCA1/2-mutant tumors to agents that damage DNA. Adding 
carboplatin to a regimen of neoadjuvant chemotherapy resulted in more than 
20% increase in pCR in women with TNBC (von Minckwitz, 2013). Another 
study confirmed that adding carboplatin or carboplatin and bevacizumab to 
standard neoadjuvant chemotherapy regimen significantly increased pCR 
rate (Sikov, 2013). In the Gepar-Quinto trial (Gerber et al., 2011), the 
addition of bevacizumab to standard neoadjuvant chemotherapy with a 
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sequential anthracycline and taxane regimen produced a significantly higher 
rate of pCR in the TNBC patients, no data on long-term follow-up are 
available yet. In a very small study involving 25 BRCA-mutation carriers 
80% of whom had TNBC, 4 cycles of single agent cisplatin produced a pCR 
rate of 72% (Gronwald, 2009). Two additional studies evaluated the same 
regimen in TNBC patients and reported pCR rates of 21% (Silver, 2010) and 
15% (Ryan, 2009). There is a lack of randomized trial data. 
 Neoadjuvant regimens without anthracyclines were evaluated in 
patients with TNBC. Carboplatin plus weekly paclitaxel yielded pCR rate of 
67% in patient subset with TNBC (Sikov, 2009). Another study looked at a 
platinum-containing regimen without anthracycline or taxane in triple 
negative and BRCA-mutated patients (Telli, 2013). Carboplatin,  
gemcitabine and iniparib was given for 6 cycles, pCR rate of 36% was 
achieved in the overall population, but triple negative patients who also had 
BRCA-mutations had pCR rate of 56%.  
TNBC may have higher metastatic potential, with increased 
probability for visceral and central nervous system metastases versus bone 
metastases (Liedtke, 2008; Lin, 2008). We observed similar results, of 17 
patients with distant relapse, 6 had brain metastases, 5 lung, 4 liver and only 
2 patients had bone metastases. 
Study by Liedtke et al. showed that despite significantly higher pCR 
rates (22% versus 11%, p=0.034), patients with TNBC had decreased 3-year 
progression-free (p<0.0001) and 3-year overall survival rates (p<0.0001) 
compared with non-TNBC (Liedtke, 2008). If pCR was achieved, patients 
had similar overall survival regardless of receptor status. Our results show 
that TNBC patients with pCR have excellent disease free and overall 
survival. However in the setting of residual disease after neoadjuvant 
chemotherapy, the overall prognosis of the disease is poor, half of the 
patients had disease recurrence and died from breast cancer.  
A pCR can be considered as a reliable surrogate marker for disease 
free and overall survival in patients with TNBC (von Minckwitz, 2011). 
Patients can be relieved from unfavourable prognosis in case a pCR is 
diagnosed, patients without pCR are at high need for new treatment options. 
However it is not clear how to predict response to neoadjuvant 
treatment and which patients with TNBC are more likely to experience pCR.  
It is proved that TNBC is not a homogeneous group. Gene expression 
analyses have identified molecular subtypes of TNBC (Lehmann, 2011; 
Rouzier, 2005). Lehmann and Bauer et al. classified TNBC into 7 subtypes 
by gene expression microarray. Heterogeneous response of TNBC to 
neoadjuvant chemotherapy suggests that different subtypes of TNBC may be 
associated with different pCR rates. In addition, some molecular drivers in 
TNBC subtypes that can be therapeutically targeted are identified. Gene 
European Scientific Journal   April 2014  edition vol.10, No.12   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
32 
expression microarray was performed in 130 TNBC patients who received 
standard neoadjuvant chemotherapy (Masuda, 2013). Molecular subtypes of 
TNBC have different response rates to neoadjuvant chemotherapy, 28% pCR 
rate for all patients (range 0-52% for particular subgroups). Lehmann and 
Bauer‘s classification has a strong impact because it classifies all TNBC 
population into 7 homogeneous subtypes, and subtype classification had a 
predictive preclinical effect on the outcome of therapy that incorporate 
specific targeted treatments, as an androgen receptor antagonist and 
PI3K/mTOR inhibitor. Study by Masuda et al. showed that 7 TNBC 
subtypes predicted the rate of pCR to current standard chemotherapy 
regimens. 
This study has a number of limitations. It is retrospective analysis, 
patient sample is small and heterogenous regarding initial tumor size, nodal 
status, stage and number of neoadjuvant chemotherapy cycles received. 
Nonetheless, it clearly showed that pCR correlates with prognosis in patients 
with TNBC.  
 
Conclusion 
Patients with TNBC who have a pCR in the breast and axillary nodes 
have a significantly improved disease-free and overall survival rate 
compared with patients with residual disease after neoadjuvant 
chemotherapy.  
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